Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in Amyloid Cardiomyopathy
NCT05795400Completed
- Start
- Jun 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of dapagliflozin in amyloid cardiomyopathy and heart failure (HF) (2 arms). Primary endpoints: Kansas City Cardiomyopathy Questionnaire Summary Score at 6 months, 6 Minute Walk Test Distance at 6 months and 1 more. Started Jun 2022; status: completed.
02
Drugs
dapagliflozin
03
Conditions
amyloid cardiomyopathyheart failure (HF)
Beyond the preview
Go deeper on NCT05795400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05795400.